Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23069194.
- Also identified by DOI 10.1016/j.jpeds.2012.08.035.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Diffuse cutaneous mastocytosis is a less common but potentially life-threatening variant of childhood mastocytosis. Here we report 2 children with diffuse cutaneous mastocytosis in whom an activating somatic KIT mutation was detected. Treatment with imatinib, a KIT inhibitor, resulted in resolution of the lesions and were well tolerated by the patients.
Medical subject headings
- Mastocytosis, Cutaneous
- Piperazines
- Protein Kinase Inhibitors
- Pyrimidines